Number of cases (%) | ||
Age | Mean | 59.5 |
Range | 38–75 | |
Gender | Male | 24 (68.8) |
Female | 11 (31.3) | |
Histology | Adenocarcinoma | 25 (71.4) |
Squamous cell carcinoma | 8 (22.9) | |
Large cell carcinoma | 1 (2.9) | |
Atypical carcinoid | 1 (2.9) | |
Performance status | 0 | 3 (8.6) |
1 | 32 (91.4) | |
Clinical staging | c-stage IIIB | 6 (17.1) |
c-stage IV | 20 (57.1) | |
Recurrence | 9 (25.7) | |
EGFR mutation status | Wild | 28 (80) |
Mutation | 7 (20) | |
Prior treatment | Platinum-based chemotherapy | 30 (85.7) |
Gefitinib | 5 (14.3) | |
Surgery | 11 (31.4) | |
Radiation therapy | 11 (31.4) |